Overview

* BridgeBio Q3 revenue rises to $120.7 mln, driven by Attruby's commercial launch

* Company ends Q3 with $645.9 mln in cash and marketable securities

* BridgeBio plans NDA filings for BBP-418 and encaleret in 1H 2026

Outlook

* Topline results for PROPEL 3 study of infigratinib expected in early 2026

Result Drivers

* ATTRUBY LAUNCH - Strong commercial launch of Attruby contributed $108.1 mln to Q3 revenue, driven by increasing prescriptions and physician adoptionimprovements in serum and urine calcium levels

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.95

Q3 Net -$184.94

Income mln

Q3 -$145.2

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 18 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for BridgeBio Pharma Inc ( BBIO ) is $71.00, about 9.2% above its October 28 closing price of $64.50

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)